Advanced search
Publication Cover
Leukemia & Lymphoma Volume 49, 2008 - Issue 1
Submit an article Journal homepage
31
Views
2
CrossRef citations to date
0
Altmetric
Commentary

High dose therapy for light chain amyloidosis: Can we reduce treatment related mortality further?

Meletios Dimopoulos Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, GreeceCorrespondence[email protected]
&
Efstathios Kastritis Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
Pages 4-5 | Published online: 01 Jul 2009

References

  • Comenzo R L, Gertz M A. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276–4282
  • Dispenzieri A, Kyle R A, Lacy M Q, Therneau T M, Larson D R, Plevak M F, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004; 103: 3960–3963
  • Skinner M, Sanchorawala V, Seldin D C, Dember L M, Falk R H, Berk J L, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85–93
  • Seldin D C, Anderson J J, Skinner M, Malek K, Wright D G, Quillen K, et al. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 2006; 108: 3945–3947
  • Leung N, Leung T R, Cha S S, Dispenzieri A, Lacy M Q, Gertz M A. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood 2005; 106: 3353–3357
  • Sanchorawala V, Wright D G, Seldin D C, Falk R H, Finn K T, Dember L M, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 2004; 33: 381–388
  • Gertz M, Lacy M, Dispenzieri A, Hayman S, Kumar S, Buadi F, Leung N, Litzow M. Troponin T as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 2008; 49: 36–41
  • Dispenzieri A, Kyle R A, Gertz M A, Therneau T M, Miller W L, Chandrasekaran K, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361: 1787–1789
  • Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083–1093
  • Seldin D C, Skinner M, Oran B, Quillen K, Finn K T, Sanchorawala V. Relapse rate and long-term survival of AL amyloidosis patients treated with high-dose melphalan and autologous stem cell transplantation (HDM/SCT). Blood (Suppl.) 2006; 108: 3094

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.